Investing in sales enablement intelligence data for the pharmaceutical industry is a strategic move that can lead to a significant return on investment. By utilising a sales intelligence database, ...

David Lebowitz, an analyst from Citi, maintained the Buy rating on BridgeBio Pharma (BBIO – Research ... with Pfizer’s pricing strategy. This competitive pricing, coupled with an emphasis ...

On Monday, BridgeBio Pharma, Inc. (NASDAQ ... benefit as an important factor for market share in the lucrative, but competitive, ATTR-CM space.” Price Action: BBIO stock is up 0.85% at $22. ...

the pharmaceutical industry has been highlighted as one of the biggest contributors to global emissions,” said the authors of a whitepaper from climate intelligence specialists, Cervest.

The pharma industry has rapidly embraced digitalisation as a way to transform its sales engagement, but there has been little to show for the effort. That is the premise of a new book by pharma ...

On Friday, the FDA approved BridgeBio Pharma, Inc.’s (NASDAQ:BBIO) Attruby (acoramidis), an orally-administered near-complete (≥90%) stabilizer of Transthyretin (TTR) for adults with ATTR-CM ...

Kostas Biliouris, an analyst from BMO Capital, maintained the Hold rating on BridgeBio Pharma (BBIO – Research ... such as the competitive dynamics with the existing Tafamidis and the need ...

28 November 2024 Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J ...

Also Read: BridgeBio Pharma’s Lead Candidate Cuts Mortality ... as an important factor for market share in the lucrative, but competitive, ATTR-CM space.” Price Action: BBIO stock is up ...

Given the pace with which machine learning systems are growing, this book provides a good base for anyone shifting to this field. The author talks about machine intelligence’s historical background ...